Atossa Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATOS Nasdaq 2836 www.atossatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atossa Therapeutics, Inc.

Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run - Jul 21st, 2026 3:17 pm
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - Jul 21st, 2026 6:30 am
ATOS: Raises up to $16.5 Million in Registered Direct Offering - Jul 1st, 2026 7:08 am
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - Jun 12th, 2026 3:30 pm
Top Midday Decliners - Jun 11th, 2026 11:47 am
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds - Jun 11th, 2026 6:00 am
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment - Jun 10th, 2026 10:51 am
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics - Jun 1st, 2026 3:05 am
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - May 27th, 2026 6:30 am
Atos Selected by Viasat to Modernize Global Digital Workplace Operations - May 19th, 2026 9:09 am
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - May 14th, 2026 6:30 am
ATOS: Initiating Coverage of Atossa Therapeutics; Endoxifen’s Expanding Opportunity from Oncology to Orphan Disease - May 13th, 2026 1:00 am
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - May 8th, 2026 6:45 am
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women - May 6th, 2026 6:30 am
Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement - May 5th, 2026 8:49 am
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - May 4th, 2026 6:30 am
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service - Mar 31st, 2026 5:00 am
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Mar 25th, 2026 3:30 pm
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - Mar 19th, 2026 6:00 am
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - Mar 12th, 2026 6:00 am